Temozolomide in Metastatic Breast Cancer Patients at High Risk of Brain Recurrence: Impact on the Incidence of Brain Metastases (STOP).

Trial Profile

Temozolomide in Metastatic Breast Cancer Patients at High Risk of Brain Recurrence: Impact on the Incidence of Brain Metastases (STOP).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Advanced breast cancer; Brain metastases
  • Focus Therapeutic Use
  • Acronyms STOP
  • Sponsors Schering-Plough
  • Most Recent Events

    • 11 Mar 2011 Planned end date changed from Apr 2011 to Jun 2010 as reported by ClinicalTrials.gov.
    • 11 Mar 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 09 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top